A recent study presented at the 2023 ASCO Annual Meeting called DIPLOMA found that minimally invasive distal pancreatectomy (MIDP) is a safe and effective alternative to traditional open surgery for early-stage pancreatic cancer. In a trial with 258 patients, MIDP had similar outcomes to open surgery in terms of tumor removal, lymph node yield, and recurrence. This marks a significant shift in the standard of care, as MIDP offers quicker recovery, less pain, and shorter hospital stays for patients with resectable pancreatic cancer.
